Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiespectus Compared to Aflibercept in Neovascular Age-related Macular Degeneration
NCT07496567Phase 3Recruiting
- Sponsor
- EyeBio
- Start
- Apr 2026
- Primary completion
- Jul 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of tiespectus in neovascular age-related macular degeneration (NVAMD), sponsored by EyeBio. Started Apr 2026; status: recruiting.
02
Drugs
tiespectus
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07496567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496567.